Hou Zong-liu, Liu Ying, Mao Xi-Hong, Wei Chuan-yu, Meng Ming-yao, Liu Yun-hong, Zhuyun Yang Zara, Zhu Hongmei, Short Martin, Bernard Claude, Xiao Zhi-cheng
Yan-an Hospital; Kunming Medical University; Kunming, PR China.
The Key Laboratory of Stem Cell and Regenerative Medicine; Institute of Molecular and Clinical Medicine; Kunming Medical College; Kunming, PR China; Department of Anatomy and Developmental Biology; Monash University; Clayton, Victoria, Australia.
Cell Adh Migr. 2013 Sep-Oct;7(5):404-7. doi: 10.4161/cam.26941. Epub 2013 Oct 30.
There is currently great interest in the use of mesenchymal stem cells as a therapy for multiple sclerosis with potential to both ameliorate inflammatory processes as well as improve regeneration and repair. Although most clinical studies have used autologous bone marrow-derived mesenchymal stem cells, other sources such as allogeneic umbilical cord-derived cells may provide a more accessible and practical supply of cells for transplantation. In this case report we present the treatment of aggressive multiple sclerosis with multiple allogenic human umbilical cord-derived mesenchymal stem cell and autologous bone marrow-derived mesenchymal stem cells over a 4 y period. The treatments were tolerated well with no significant adverse events. Clinical and radiological disease appeared to be suppressed following the treatments and support the expansion of mesenchymal stem cell transplantation into clinical trials as a potential novel therapy for patients with aggressive multiple sclerosis.
目前，人们对使用间充质干细胞治疗多发性硬化症有着浓厚的兴趣，因为它有潜力改善炎症过程，并促进再生和修复。尽管大多数临床研究使用的是自体骨髓来源的间充质干细胞，但其他来源，如同种异体脐带来源的细胞，可能为移植提供更易获取且实用的细胞供应。在本病例报告中，我们展示了在4年时间里，使用多次同种异体人脐带来源的间充质干细胞和自体骨髓来源的间充质干细胞治疗侵袭性多发性硬化症的情况。治疗耐受性良好，未出现明显不良事件。治疗后临床和影像学疾病似乎得到了抑制，这支持将间充质干细胞移植扩展到临床试验中，作为侵袭性多发性硬化症患者的一种潜在新疗法。
